Metraipolis › archive › dc_da133fd7342b

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial — Europe PMC PMID:42120723

Source: Europe PMC (en)
Original: https://europepmc.org/article/MED/42120723
DOI: 10.1038/s41591-[numero omesso]-7
License (as archived): solo-consultazione
Archived: 2026-11-02T11:02:36.650Z
SHA-256 of the archived text: 59209ed6ce04e1026f79f3a208b0a18e8ccbc32243b194dabc2c02a59dfeefbe
Stable URL of this page: https://metraipolis.com/documento/dc_da133fd7342b

How to cite

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial — Europe PMC PMID:42120723 — Europe PMC (en), https://europepmc.org/article/MED/42120723 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_da133fd7342b (Metraipolis archive dc_da133fd7342b, sha256 59209ed6ce04e1026f79f3a208b0a18e8ccbc32243b194dabc2c02a59dfeefbe)

BibTeX

@misc{dcda133fd7342b,
  title = {Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial — Europe PMC PMID:42120723},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42120723},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_da133fd7342b; sha256 59209ed6ce04e1026f79f3a208b0a18e8ccbc32243b194dabc2c02a59dfeefbe},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42120723. Agents can read the archived copy with the MCP tool read_document.